Nina Tatarova

Nina Tatarova

Auto-generated profile, based on publicly available information

Nina Tatarova

Pavlov University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2019 in American Journal of Perinatology
Verified
Journal Article
Open access
PDF file
SBSean C. Blackwell
Sean C. Blackwell
CGCynthia Gyamfi-Bannerman
Cynthia Gyamfi-Bannerman
JBJoseph R. Biggio
Joseph R. Biggio
SCSuneet P. Chauhan
Suneet P. Chauhan
BHBrenna L. Hughes
Brenna L. Hughes
JKJulie Krop
Julie Krop
Background Women with a history of spontaneous preterm birth (SPTB) are at a significantly increased risk for recurrent preterm birth (PTB). To date, only one large U.S. clinical trial comparing 17-OHPC (17-α-hydroxyprogesterone caproate or “17P”) to placebo has been published, and this trial was stopped early due to a large treatment benefit. Objective This study aimed to assess whether 17-OHPC decreases recurrent PTB and neonatal morbidity in women with a prior SPTB in a singleton gestation. Study Design This was a double-blind, placebo-controlled international trial involving women with a previous singleton SPTB (clinicaltrials.gov: NCT 01004029). Women were enrolled at 93 clinical centers (41 in the United States and 52 outside the United States) between 160/7 to 206/7 weeks in a 2:1 ratio, to receive either weekly intramuscular (IM) injections of 250 mg of 17-OHPC or an inert oil placebo; treatment was continued until delivery or 36 weeks. Co-primary outcomes were PTB < 35 weeks and a neonatal morbidity composite index. The composite included any of the following: neonatal death, grade 3 or 4 intraventricular hemorrhage, respiratory distress syndrome, bronchopulmonary dysplasia, necrotizing enterocolitis, or proven sepsis. A planned sample size of 1,707 patients was estimated to provide 98% power to detect a 30% reduction in PTB < 35 weeks (30% to 21%) and 90% power to detect a 35% reduction in neonatal composite index (17%–11%) using a two-sided type-I error of 5%. Finally, this sample size would also provide 82.8% power to rule out a doubling in the risk of fetal/early infant death assuming a 4% fetal/early infant death rate. Analysis was performed according to the intention-to-treat principle. Results Baseline characteristics between the 1,130 women who received 17-OHPC and 578 women who received placebo were similar. Overall, 87% of enrolled women were Caucasian, 12% had >1 prior SPTB, 7% smoked cigarettes, and 89% were married/lived with partner. Prior to receiving study drug, 73% women had a transvaginal cervical length measurement performed and <2% had cervical shortening <25 mm. There were no significant differences in the frequency of PTB < 35 weeks (17-OHPC 11.0% vs. placebo 11.5%; relative risk = 0.95 [95% confidence interval (CI): 0.71–1.26]) or neonatal morbidity index (17-OHPC 5.6% vs. placebo 5.0%; relative risk = 1.12 [95% CI: 0.68–1.61]). There were also no differences in frequency of fetal/early infant death (17-OHPC 1.7% vs. placebo 1.9%; relative risk = 0.87 [95% CI: 0.4–1.81]. Maternal outcomes were also similar. In the subgroup of women enrolled in the United States (n = 391; 23% of all patients), although the rate of PTB < 35 weeks was higher than the overall study population, there were no statistically significant differences between groups (15.6% vs. 17.6%; relative risk = 0.88 [95% CI: 0.55, 1.40]. Conclusion In this study population, 17-OHPC did not decrease recurrent PTB and was not associated with increased fetal/early infant death. In women with a prior spontaneous preterm birth, weekly 17-OHPC compared with placebo did not reduce recurrent preterm birth or decrease neonatal morbidity. Date of registration: October 27, 2009. Date of initial participant enrollment: November 12, 2009. Clinical trials ID: NCT01004029. URL: https://clinicaltrials.gov/ct2/show/NCT01004029?term=17P+AMAG&rank=2.

19 September 2019 in Effective Pharmacotherapy
Verified
Journal Article
Closed access
AUAcademician I.P. Pavlov First St. Petersburg State Medical University
Academician I.P. Pavlov First St. Petersburg State Medical University
MAM.S. Ayrapetyan
M.S. Ayrapetyan
VAV.A. Avalyan
V.A. Avalyan
NTN.A. Tatarova
N.A. Tatarova
SSSaint Petersburg Iclinic Sz
Saint Petersburg Iclinic Sz
Проведена оценка риска перинатальных осложнений и преждевременных родов у женщин с железодефицитной анемией. Были ретроспективно изучены истории родов 303 рожениц

9 September 2021 in Obstetrics, Gynecology and Reproduction
Verified
Journal Article
Open access
PDF file
VBV. F. Bezhenar
V. F. Bezhenar
LIL. A. Ivanova
L. A. Ivanova
NTN. A. Tatarova
N. A. Tatarova
MKM. Yu. Korshunov
M. Yu. Korshunov
Aim: to identify factors predisposing to perinatal losses, assessment of which is available at the first (only) visit of pregnant woman in antenatal clinic.Materials and Methods. A retrospective analysis of the medical records of 964 women who performed delivery in 2009-2019 in 15 obstetric facilities was carried out. The patients were divided into 2 groups: the main group included 457 women with perinatal losses (stillbirth - 328 children, and 129 children with early neonatal death); the control group consisted of 507 women, whose children survived 7 days during postnatal period. We analyzed parameters routinely determined by an obstetrician-gynecologist at the first visit of woman during within ongoing pregnancy (regardless of gestation age), namely, social status, anamnesis, data of initial examination.Results. The following significant differences were revealed in pregnant women from the main group: a younger age of pregnancy; no registered marriage and permanent job as well as primary and secondary education; smoking, alcohol and drug use; concurrent diabetes mellitus, hypertensive disorders, blood contact infections, obesity; older menarche age and younger sexual debut age; medical history contains infectious genital pathology, more often pregnancies and childbirths, two or more abortions before repeated childbirth, premature births.Conclusion. Thus, the anamnestic indicators noted above can be used to create prognostic statistical systems and models to determine high risk of perinatal losses of any nature.

29 May 2020 in Akusherstvo i ginekologiia
Verified
Journal Article
Closed access
PPPlekhanov A.N. Plekhanov
Plekhanov A.N. Plekhanov
BBBezhenar V.F. Bezhenar
Bezhenar V.F. Bezhenar
EEEpifanova Т.A. Epifanova
Epifanova Т.A. Epifanova
BFBezhenar F.V. Bezhenar F
Bezhenar F.V. Bezhenar F
SSShishkina Yu.S Shishkina
Shishkina Yu.S Shishkina
SCSaint Petersburg Sm-Clinic Medical Center
Saint Petersburg Sm-Clinic Medical Center

23 November 2020 in GYNECOLOGY
Verified
Journal Article
Open access
PDF file
NTNina A. Tatarova
Nina A. Tatarova
MAMargarita S. Airapetian
Margarita S. Airapetian
Vitamin D is a regulator of immune response, and plays a role in the development of cardiovascular diseases, insulin resistance and diabetes mellitus, obesity, autoimmune disorders, iron binding, anemia, respiratory viral and other diseases. In addition, vitamin D deficiency contributes to the chronicity of infections and an increased risk for number of oncological pathology. The developing immunosuppression in women with iron deficiency anemia in the menopausal transition period does not allow to fully compensate for iron deficiency with monotherapy if vitamin D deficiency is present. The drug of choice in this situation is micellized (water-soluble) vitamin D3(Aquadetrim).

28 September 2020 in Journal of obstetrics and women's diseases
Verified
Journal Article
Open access
PDF file
VBVitaly F. Bezhenar
Vitaly F. Bezhenar
BAByuzand V. Arakelyan
Byuzand V. Arakelyan
VLViktor A. Linde
Viktor A. Linde
IKIrina A. Kuznetsova
Irina A. Kuznetsova
NTNina A. Tatatrova
Nina A. Tatatrova
АВАракелян Бюзанд Вазгенович
Аракелян Бюзанд Вазгенович
A clinical observation of endometrioid infiltrate of a postoperative scar formed as a result of surgical delivery by cesarean section is presented in this article.